|Bid||82.75 x 900|
|Ask||0.00 x 1100|
|Day's Range||80.70 - 82.75|
|52 Week Range||65.44 - 88.76|
|Beta (3Y Monthly)||0.80|
|PE Ratio (TTM)||50.42|
|Forward Dividend & Yield||1.28 (1.60%)|
|1y Target Est||N/A|
Tandem Diabetes stock popped Tuesday on a partnership deal with medical behemoth Abbott Laboratories in diabetes treatment. The medical technology firms will integrate their medical devices.
Abbott (ABT) has been growing popular with developments in its flagship, market leading device for the treatment of mitral regurgitation, MitraClip.
Abbott Laboratories Inc. said in a Tuesday filing that its board had authorized an additional $3 billion in share repurchases. The company said there is still a $795 million unused portion of its prior buyback program, which received approval in September 2014. Also on Tuesday, Abbott Labs announced that it would partner with Tandem Diabetes Care on diabetes-management options. Abbott Labs shares are up 0.9% in premarket trading Tuesday. The stock has risen 10% so far this year, as the S&P 500 has gained 18%.
DexCom shares fell Tuesday after rival Tandem Diabetes Care said it was partnering with Abbott Labs to develop a new insulin pump featuring Abbott's glucose-sensing technology. Tandem and Abbott "can provide new ways for people to manage their diabetes" that "can integrate easily into their daily lives, especially people who rely on insulin pumps," Abbott Vice President Jared Watkin said in a statement. The partnership ends exclusivity for DexCom in the space and exposes 15% of the company's sales to competition, according to Bloomberg.
Abbott Laboratories rises after the medical device company says its board had authorized an additional $3 billion in share repurchases.
Abbott (ABT) is steadily gaining prominence for developments in its flagship, sensor-based continuous glucose monitoring (CGM) system of FreeStyle Libre.
A long-speculated expansion project by one of Tipp City's largest employers has finally been confirmed.
The coming week’s docket of economic reports and earnings releases comes just following the Trump administration’s announcement of a partial trade deal with China late last week.
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing more than 730 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of June […]
Dexcom stock is in a holding pattern near a buy point out of a cup base as investors await a rival diabetes treatment medical device from medical technology company Abbott Laboratories.
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Abbott...
While all stocks present potential investor risk, some have traditionally fared better than others, during down markets. The following five stocks appreciated in value, from 2007-2009, holding up exceptionally well during the 2008 financial crisis.
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll look at...
The regulatory go-ahead for Abbott's (ABT) ARCHITECT STAT High Sensitivity Troponin-I blood test is a major stride forward in its commitment for detecting patients suspected of having a heart attack.
Medtronic's (MDT) DAPT study's robust data outcome is likely to aid as the therapy duration might prove to be a superior treatment option.